Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydroxocobalamin + butyrate is a combination of two agents: hydroxocobalamin, a synthetic form of vitamin B12, and butyrate, a short-chain fatty acid. Hydroxocobalamin acts as an essential cofactor in DNA synthesis and cellular metabolism and is used to treat vitamin B12 deficiency, pernicious anemia, and cyanide poisoning. Butyrate serves as an energy source for colonocytes and has anti-inflammatory properties in the gut. This combination has been studied for its potential to reduce intestinal inflammation (as measured by calprotectin) in conditions such as inflammatory bowel disease or other gastrointestinal disorders[1][2]. The mechanism involves supporting cellular metabolism (hydroxocobalamin) and modulating gut inflammation (butyrate).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxocobalamin + butyrate.